Входя на эту страницу, Вы подтверждаете, что являетесь  медицинским работником.

Status message

Not the entire site translated, but only to "Magazine"

Ketamine: a new view on therapeutic opportunities in psychiatric practice

Dorovskih I.V., Pavlova T. A., Scheidegger J. M.
FGKI 1586-th clinical military hospital of the defense Ministry RF

SUMMARY

This article is a review of evidence-based research in English for the past 15 years thanks to access via a database PubMed and Medline, about the new features out of claimed indications of the well-known short-acting anesthetic, ketamine. Latter being the antagonist of NMDA receptors by activating glutamatergic transmission has antidepressant effects. One intravenous infusion of 0.5 mg/kg of ketamine for 40 minutes can provide fast antidepressant effect, during the bipolar and monopolar resistant depression, especially with high risk of suicide. Instability of antidepressant effect of ketamine from a few hours to several weeks is demonstrated. It is also proved the effectiveness of ketamine in obsessive-compulsive and posttraumatic frustration. Intramuscular, oral and intranasal routes of applications are researched. Ketamin can probably serve as a therapeutic alternative in some patients with pharmacotherapy resistant depression except patients with substance abuse or a history of psychosis.

Contact: ig.dorovskih@yandex.ru

References: 
  • 1. Alfimov P.V., Kostyukova E.G., Mosolov S.N. Sovremennye metody preodoleniya terapevticheskoi rezistentnosti pri rekurrentnoi depressii // Biologicheskie metody terapii psikhicheskikh rasstroistv (dokazatel'naya meditsina – klinicheskoi praktike) / Pod red. S.N. Mosolova. M.: Sotsial'no-politicheskaya mysl', 2012. S. 438–473.
  • 2. Biologicheskie metody terapii psikhicheskikh rasstroistv (dokazatel'naya meditsina – klinicheskoi praktike) / Pod red. S.N.Mosolova. – M.: Sotsial'no-politicheskaya mysl', 2012. – S. 285–286.
  • 3. Kuchmenko D.N., Kozlovskii V.L. Farmakodinamika ketamina kak svoistvo atipichnogo antidepressanta (obzor) // Obozrenie psikhiatrii i meditsinskoi psikhologii im. V.M. Bekhtereva. – 2013. – № 4. – S. 20–25.
  • 4. Kuchmenko D.N., Kozlovskii V.L. Ketamin – atipichnyi antidepressant ili sredstvo urgentnoi psikhotropnoi terapii? // Obozrenie psikhiatrii i meditsinskoi psikhologii im. V.M. Bekhtereva. – 2014. – № 1. – S. 3–9.
  • 5. Mazo G.E., Neznanov N.G. Terapevticheski rezistentnye depressii.– SPb.: Beresta, 2012. – 448 s.
  • 6. Mosolov S.N. Klinicheskoe primenenie sovremennykh antidepressantov. – SPb.: Meditsinskoe informatsionnoe agentstvo, 1995. – S. 21–28.
  • 7. Mosolov S.N. Sovremennye biologicheskie gipotezy rekurrentnoi depressii (obzor) // Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. – 2012. – T. 112, № 11–2. – S. 29–40.
  • 8. Aan het Rot M., Collins K.A., Murrough J.W., Perez A.M., Reich D.L., Charney D.S. et al. Safety and Efficacy of Repeated-dose Intravenous Ketamine for Treatment-resistant Depression // Biol Psychiatry. – 2010. – Vol. 67. – P. 139–145.
  • 9. Aan het Rot M., Zarate C.A. Jr., Charney D.S. et al. Ketamine for Depression: Where Do We Go from Here? // Biol Psychiatry. – 2012. – Vol. 72. – P. 537–547.
  • 10. Autry A.E., Adachi M., Nosyreva E., Na E.S., Los M.F., Cheng P.F. et. al. NMDA Receptor Blockade at Rest Triggers Rapid Behavioural Antidepressant Responses // Nature. – 2011. – Vol. 475. – P. 91–95.
  • 11. Berman R.M., Cappiello A., Anand A., Oren D.A., Heninger G.R., Charney D.S. et al. Antidepressant Effects of Ketamine in Depressed Patients // Biol Psychiatry. – 2000. – Vol. 47. – P. 351–354.
  • 12. Beurel E., Song L., Jope R.S. Inhibition of Glycogen Synthase Kinase-3 is Necessary for the Rapid Antidepressant Effect of Ketamine in Mice // Mol Psychiatry. – 2011. – Vol. 26. – P. 1068–1070.
  • 13. Bjerre J., Fontenay C. Ketamin Ved Melankolsk Depression // Ugeskr Lager. – 2010. – Vol. 172. – P. 460–461.
  • 14. Bloch M.H., Wasylink S., Landeros-Weisenberger A., Panza K.E., Billingslea E., Leckman J.F. et. al. Effects of Ketamine in Treatment-refractory Obsessive-Compulsive Disorder // Biol Psychiatry. – 2012. – Vol. 72. – P. 964–970.
  • 15. Carr D.B., Goudas L.C., Denman W.T., Brookoff D., Staats P.S., Brennen L. et al. Safety and Efficacy of Intranasal Ketamine for the treatment of Breakthrough Pain in Patients with Chronic Pain: a Randomized, Double-blind, Placebo-controlled, Crossover Study // Pain. – 2004. – Vol. 108. – P. 17–27.
  • 16. Correll G.E., Futter G.E. Two Case Studies of Patients with Major Depressive Disorder Given Low-dose (subanesthetic) Ketamine Infusions // Pain Med. – 2006. – Vol. 7. – P. 92–95.
  • 17. Denk M.C., Rewerts C., Holsboer F., Erhardt-Lehmann A., Turck C.W. Monitoring Ketamine Treatment Response in a Depressed Patient via Peripheral Mammalian Target of Rapamycin Activation // Am J Psychiatry. – 2011. – Vol. 68. – P. 751–752.
  • 18. DeWilde K.E., Levitch C.F., Murrough J.W. et al. The promise of Ketamine for Treatment-resistant Depression: Current Evidence and Future Directions // Ann NY Acad Sci. – 2015. – Vol. 1345. – P. 47–58.
  • 19. Diamond P.R. et al. Ketamine Infusions for Treatment Resistant Depression: a Series of 28 Patients Treated Weekly or Twice Weekly in an ECT Clinic // J Psychopharmacology. – April 2014.
  • 20. DiazGranados N., Ibrahim L., Brutsche N.E., Newberg A., Kronstein P., Khalife S., et al. A Randomized add-on Trial of an N-methyl-D-aspartate Antagonist in Treatment-resistant Bipolar Depression // Arch Gen Psychiatry. – 2010. – Vol. 67. – P. 793–802.
  • 21. DiazGranados N., Ibrahim L.A., Brutsche N.E., Ameli R., Henter I.D., Luckenbaugh D.A. et al. Rapid Resolution of Suicidal Ideation after a Single Infusion of an N-methyl-D-aspartate Antagonist in Patients with Treatment-resistant Major Depressive Disorder // J Clin Psychiatry. – 2010. – Vol. 71. – P. 1605–1611.
  • 22. Fond G. et. al. Ketamine administration in depressive disorders: A systematic review and meta-analysis // J Psychopharmacology. – July 2014.
  • 23. Glue P., Gulati A., Le Nedelec M., Duffull S. Dose- and Exposure-response to Ketamine in Depression // Biol Psychiatry. – 2011. – Vol. 70. – P. 9–12.
  • 24. Goforth H.W., Holsinger T. Rapid Relief of Severe Major Depressive Disorder by Use of Preoperative Ketamine and Electroconvulsive Therapy // J ECT. – 2007. – Vol. 23. – P. 23–25.
  • 25. Ibrahim L., DiazGranados N., Franco-Chaves J., Brutsche N., Henter I.D., Kronstein P. et al. Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-week, Double-blind, Placebo-controlled Study // Neuropsychopharmacology. – 2012. – Vol. 37. – P. 1526–1533.
  • 26. Ibrahim L., DiazGranados N., Luckenbaugh D.A., Machado-Vieira R., Baumann J., Mallinger A.G. et al. Rapid Decrease in Depressive Symptoms with an N-methyl-d-aspartate antagonist in ECTresistant Major Depression // Prog Neuropsychopharmacol Biol Psychiatry. – 2011. – Vol. 35. – P. 1155–1159.
  • 27. Kavalali E.T., Monteggia L.M. How Does Ketamine Elicit a Rapid Antidepressant Response? // Curr Opin Pharmacol. – 2015. – Vol. 20. – P. 35–39.
  • 28. Kranaster L., Kammerer-Ciernioch J., Hoyer C., Sartorius A. Clinically Favourable Effects of Ketamine as an Anaesthetic for Electroconvulsive Therapy: A Retrospective Study // Eur Arch Psychiatry Clin Neurosci. – 2011. – Vol. 261. – P. 575–582.
  • 29. Krystal A.D., Weiner R.D., Dean M.D., Lindahl V.H., Tramontozzi L.A 3rd, Falcone G., et al. Comparison of Seizure Duration, Ictal EEG, and Cognitive Effects of Ketamine and Methohexital Anesthesia with ECT // J Neuropsychiatry Clin Neurosci. – 2003. – Vol. 15. – P. 27–34.
  • 30. Lally N., Nugent A.C., Luckenbaugh D.A. et al. Neural Correlates of Change in Major Depressive Disorder Anhedonia Following Open-label Ketamine // J Psychopharmacol. – 2015. – Vol. 29. – P. 596–607.
  • 31. Lee Y., Syeda K., Maruschak N.A. et al. A New Perspective on the Anti-Suicide Effects with Ketamine Treatment: A Precognitive Effect // J Clin Psychopharmacol. – 2016. – Vol. 36. – P. 50–56.
  • 32. Loo C., Sainsbury K., Martin D., MacPherson R. Synergistic Antidepressant Effects with Ketamine and ECT // J ECT. – 2009. – Vol. 25. – P. 150.
  • 33. Maeng S., Zarate C.A. Jr., Du J., Schloesser R.J., McCammon J., Chen G. et. al. Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of Alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptors // Biol Psychiatry. – 2008. – Vol. 63. – P. 349–352.
  • 34. Mathew S.J, Murrough J.W., Aan het Rot M., Collins K.A., Reich D.L., Charney D.S. Riluzole for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression: A Pilot Randomized, Placebo-Controlled Continuation Trial // Int J Neuropsychopharmacol. – 2010. – Vol. 13. – P. 71–82.
  • 35. Montgomery S.A, Asberg M. A New Depression Scale Designed to be Sensitive to Change // Br J Psychiatry. – 1979. – Vol. 134. – P. 382–389.
  • 36. Morgan C.J.A., Muetzelfeldt L., Curran H.V. Consequences of chronic ketamine self-Administration upon Neurocognitive Function and Psychological Wellbeing: A 1-year Longitudinal Study // Addiction. – 2010. – Vol. 105. – P. 121–133.
  • 37. Moukaddam N.J., Hirschfeld R.M.A. Intravenous Antidepressants: A review // Depress Anxiety. – 2004. – Vol. 19. – P. 1–9.
  • 38. Murrough J.W., Collins K.A., Fields J., et al. Regulation of Neural Responses to Emotion Perception by Ketamine in Individuals with Treatment-resistant Major Depressive Disorder // Transl Psychiatry. – 2015. – Vol. 5. – P. 509.
  • 39. Murrough J.W., Gallo J.M., Collins K.A., Aan het Rot M., Charney D.S. Reply to: Dose- and Exposure Response to Ketamine in Depression // Biol Psychiatry. – 2010. – Vol. 70. – P. 11–12.
  • 40. Murrough J.W., Perez A.M., Mathew S.J., Charney D.S. A Case of Sustained Remission Following an Acute Course of Ketamine in Treatment-resistant Depression // J Clin Psychiatry. – 2011. – Vol. 72. – P. 414–415.
  • 41. Murrough J.W., Perez A.M., Pillemer S. et al. Rapid and Longer-term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-resistant Major Depression // Biol Psychiatry. – 2012, – July 26.
  • 42. Neir J., Singh Ajit S. The Role of the Glutamatergic System in Posttraumatic Stress Disorder // CNS Spectr. – 2008. – Vol. 13, No. 7. – P. 585–591.
  • 43. Newcomer J.W., Farber N.B., Jevtovic-Todorovic V., Selke G., Melson A.K., Hershey T. et al. Ketamine-induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis // Neuropsychopharmacology. – 1999. – Vol. 20. – P. 106–118.
  • 44. Okamoto N., Nakai T., Sakamoto K., Nagafusa Y., Higuchi T., Nishikawa T. Rapid Antidepressant Effect of Ketamine Anesthesia During Electroconvulsive Therapy of Treatment-resistant Depression: Comparing Ketamine and Propofol Anesthesia // J ECT. – 2010. – Vol. 26. – P. 223–227.
  • 45. Parides M.K. et. al. Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder a Randomized Clinical Trial // Jama Psychiatry. – April 2014.
  • 46. Paul R., Schaaff N., Padberg F., Moller H.J., Frodl T. Comparison of Racemic Ketamine and Sketamine in Treatment-resistant Major Depression: Report of Two Cases // World J Biol Psychiatry. – 2009. – Vol. 10. – P. 241–244.
  • 47. Phelps L.E., Brutsche N., Moral J.R., Luckenbaugh D.A., Manji H.K., Zarate C.A. Jr. Family History of Alcohol Dependence and Initial Antidepressant Response to an N-methyl-D-Aspartate Antagonist // Biol Psychiatry. – 2009. – Vol. 65. – P. 181–184.
  • 48. Pilc A., Wieronska J.M., Skolnick P. Glutamat-based antidepressants: preclinical psychopharmacology // Biol Psychiatry – 2013. – Vol. 73. – P. 1125–1132.
  • 49. Price R.B., Nock M.K., Charney D.S., Mathew S.J. Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-resistant Depression // Biol Psychiatry. – 2009. – Vol. 66, No. 5. – P. 522–526.
  • 50. Riaza Bermudo-Soriano C., Perez-Rodriguez M.M., Vaquero-Lorenzo C., Baca-Garcia E. New Perspectives in Glutamate and Anxiety // Pharmacol Biochem Behav. – 2012. – Vol. 100, No. 4. – P. 752–774.
  • 51. Rodriguez C.L., Kegeles L.S., Flood P., Simpson H.B. Rapid Resolution of Obsessions After an Infusion of Intravenous Ketamine in a Patient with Treatment-resistant Obsessive-compulsive Disorder // J Clin Psychiatry. – 2011. – Vol. 72. – P. 567–569.
  • 52. Rodriguez C.L., Kegeles L.S. et. al. Randomized Controlled Crossover Trial of Ketamine in Obsessive-compulsive Disorder: Proof-of-concept // Neuropsychopharmacology. – 2013. – Vol. 38. – P. 2475–2483.
  • 53. Sanacora G., Kendell S.F., Levin Y., Simen A.A., Fenton L.R., Coric V. et al. Preliminary Evidence of Riluzole Efficacy in Antidepressant-treated Patients with Residual Depressive Symptoms // Biol Psychiatry. – 2007. – Vol. 61. – P. 822–825.
  • 54. Steru L., Chermat R., Thierry B., Simon P. The Tail Suspension Test: A New Method for Screening Antidepressants in Mice // Psychopharmacology (Berl). – 1985. – Vol. 85. – P. 367–370.
  • 55. Trullas R., Skolnick P. Functional Antagonists at the NMDA Receptor Complex Exhibit Antidepressant Actions // Eur J Pharmacol. – 1990. – Vol. 185. – P. 1–10.
  • 56. Valentine G.W., Mason G.F., Gomez R., Fasula M., Watzl J., Pittman B. et al. The Antidepressant Effect of Ketamine is not Associated with Changes in Occipital Amino Acid Neurotransmitter Content as Measured by [(1)H]-MRS // Psychiatry Res Neuroimaging. – 2011. – Vol. 191. – P. 122–127.
  • 57. Zarate C.A Jr., Singh J.B., Carlson P.J., Brutsche N.E., Ameli R., Luckenbaugh D.A. et al. A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-resistant Major Depression // Arch Gen Psychiatry. – 2006. – Vol. 63. – P. 856–864.
  • 58. Zarate C.A. Jr., Brutsche N.E., Ibrahim L. et al. Replication of Ketamine’s Antidepressant Efficacy in Bipolar Depression: A Randomized Controlled Add-on Trial // Biol Psychiatry. – 2012.–Vol. 71, No. 11. – P. 939–946.
  • 59. Zarate C.A. Jr., Payne J.L., Quiroz J., Sporn J., Denicoff K.K., Luckenbaugh D. et al. An Open-label Trial of Riluzole in Patients with Treatment-resistant Major Depression // Am J Psychiatry. – 2004. – Vol. 161. – P. 171–174.
  • 60. Zarate C.A. Jr., Quiroz J.A, Singh J.B., Denicoff K.D., De Jesus G., Luckenbaugh D.A. et al. An Open Label Trial of the Glutamate-modulating Agent Riluzole in Combination with Lithium for the Treatment of Bipolar Depression // Biol Psychiatry. – 2005. – Vol. 57. P. 430–432.